ClinicalTrials.gg
Active, not recruitingNCT04871282RINGSIDEUpdated Jun 8, 2026

A Study of AL102 in Patients With Progressing Desmoid Tumors

A Phase 2/3 interventional study of AL102 and Placebo in Desmoid and Desmoid Tumor, sponsored by Immunome, Inc.. Active, not recruiting at 53 sites in 11 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Immunome, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Desmoid Tumors with a site in United States — 6 open to participants now, 9 under way, 1 of them phase 3. Desmoid Tumors · United States.

Enrollment
3rd of 24
198 · median 43
Started
2021
with 1 other
Phase 2/3
Only one
of the 33
Registered
27th of 33
by date
Lead sponsor
1 of 33
Immunome, Inc.

Among the 33 studies in Desmoid Tumors with a site in United States, this one is the 3rd largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2021, is the only one in phase 2/3, and was the 27th registered.

Desmoid Tumors

71 studies on the registry are indexed under Desmoid Tumors; 21 are open to participants now.

Browse Desmoid Tumors studies →

Open to participants now

6 of the 33 studies in Desmoid Tumors with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Desmoid Tumors studies recruiting now, 13 (76%) set no upper age limit and 4 (24%) stop at 75 or younger; 6 take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Desmoid Tumors with a site in United States, or all of them as a file.
02

Study summary

The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.

Read the detailed description

This is a Phase 2/3, randomized study in subjects with progressive desmoid tumors consisting of 2 parts. Phase2/Part A is an open-label, dose regimen finding study; Phase3/Part B is a double blind, placebo-controlled study and Open Label Extension utilizing the dose regimen selected in Phase2/Part A.

03

Conditions studied

  • Desmoid
  • Desmoid Tumor

Browse trials for

Keywords

  • RINGSIDE
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Part A:

  1. At least 18 years of age (inclusive) at the time of signing the form (ICF).
  2. confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent).
  3. Disease progression, assessed locally by the investigator, defined as having at least one of the following:

    • Unidimensional growth of desmoid tumor(s) by ≥10%, using the sum of the largest diameters of target lesion(s), within 18 months of the screening MRI
    • Having desmoid tumor-related pain that is not adequately controlled with nonopioid medication
  4. At least 1 amenable to volume measurements by MRI at screening
  5. One of the following:

    • Treatment naïve subjects for whom, in the opinion of the investigator, the IP is deemed appropriate, OR
    • Recurrent/ disease following at least one (including surgery, radiation, or systemic therapy)
  6. Agrees to provide formalin-fixed paraffin embedded archival or fresh tumor tissue for re-confirmation of disease.
  7. Must be able to swallow whole capsules with no GI condition affecting absorption; nasogastric or G-tube administration is not allowed.

Inclusion Criteria Part B

  1. ≥12 years of age (inclusive) and ≥ 40 kg at the time of signing the ICF.
  2. Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent) that has progressed by ≥ 20% as measured by v1.1 within 12 months of the screening visit scan.
  3. Evidence of measurable disease by CT/MRI scan. Measurable lesions are defined according to RECIST v1.1.
  4. Subject and/or legally authorized representative (i.e. parent/guardian) must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF.
  5. Minor subjects must be capable of giving written assent as appropriate per the applicable age (per local regulatory requirements).

OLE Key Inclusion Criteria:

1. One of the following:

  1. Participated in Part A (including MRI at Week 16) and were still on study at time that Part B/OLE dose selection was made, OR
  2. Participating in Part B and were noted to have radiographic progressive disease by BICR, OR
  3. Are on study treatment (placebo or varegacestat) after completion of Part B

Exclusion Criteria Parts A and B:

  1. Diagnosed with a in the past 2 years with some exceptions.
  2. Current or recent (within 2 months of IP administration) GI disease or disorders that increase the risk of diarrhea, such as inflammatory bowel disease and Crohn's disease.
  3. Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy ≤7 days prior to administration of IP such as known active infection with , , or (HIV) at Screening.
  4. Myocardial infarction within 6 months prior to enrollment, greater than Class 1 angina pectoris, or has (NYHA) Class III or IV heart failure, symptomatic ventricular arrhythmias, sustained ventricular tachycardia, Torsade's de Pointes (TdP), the long syndrome, pacemaker dependence, or electrocardiographic evidence of acute ischemia.
  5. Unstable or severe uncontrolled medical condition (e.g., unstable cardiac or pulmonary function or uncontrolled diabetes) or any important medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the risk to the subject associated with his or her participation in the study.
  6. Pregnant or breastfeeding or expecting to conceive children within the projected duration of the study.
  7. (ECOG) performance status ≥2
  8. Abnormal organ and marrow function at Screening defined as:

    1. Neutrophils \<1000/mm3,
    2. count \<100,000/mm3,
    3. \<9 g/dL,
    4. Total >1.5x (ULN) (except known Gilbert's syndrome),
    5. (AST) and alanine aminotransferase (ALT) >2.5x ULN,
    6. Serum creatinine > ULN and (CrCl) \<60 mL/min (calculation of CrCl will be based on acceptable institution standard)
    7. Uncontrolled triglyceride ≥Grade 2 elevations per (CTCAE) v5.0 (>300 mg/dL or >3.42 mmol/L).
  9. Exclusions

    1. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥450 msec.
    2. QRS duration > 110 ms
    3. PR interval > 240 ms
    4. Marked ST-T wave abnormalities which would make it difficult to measure the QT interval
  10. Any treatments for desmoid tumors within 4 weeks prior to first dose of therapy; subject must have recovered from therapy related toxicity to \< CTCAE Grade 2 or clinical baseline. Therapy includes:

    1. Locoregional tumor directed therapies such as major surgery, radiation, radiofrequency ablation, or cryosurgery
    2. Systemic therapy including chemotherapy, biologic (anti-neoplastic agent, antibodies), TKIs (e.g., sorafenib, pazopanib, imatinib), hormonal therapy, or investigational therapy
  11. Chronic NSAIDs for the treatment of desmoid tumors within 4 weeks of first dose of IP

OLE Key Exclusion Criteria:

  1. Unstable or severe uncontrolled medical condition (e.g., unstable cardiac or pulmonary function or uncontrolled diabetes) or any important medical illness, abnormal ECG or abnormal laboratory finding that would, in the investigator's judgment, increase the risk to the participant associated with his or her participation in the study.
  2. Any participant with an ongoing TEAE (including abnormal laboratory results) from Part A or Part B that requires discontinuation from the study, will not be eligible to enter the open-label extension.
  3. Breastfeeding or expecting to conceive children within the projected duration of the study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    Part A Main Study 1.2 mg daily

    AL102 1.2 mg

    Drug: AL102

  • Experimental
    Part A Main Study 2 mg Intermittent

    AL102 2 mg

    Drug: AL102

  • Experimental
    Part A Main Study 4 mg Intermittent

    AL102 4 mg

    Drug: AL102

  • Experimental
    Part B AL102

    AL102, recommended dose regimen from Part A, 1.2 mg daily

    Drug: AL102

  • Placebo comparator
    Part B Placebo

    Placebo to match recommended dose regimen from Part A

    Other: Placebo

  • Experimental
    Open Label Extension

    AL102, recommended dose regimen from Part A, 1.2 mg daily

    Drug: AL102

Interventions

  • DrugAL102

    AL102 is an inhibitor of gamma secretase-mediated Notch signaling.

    Also known as: varegacestat

  • OtherPlacebo

    Placebo to match AL102

06

What researchers measure

Primary outcomes

  1. Part A: Safety and Tolerability - Adverse Events

    Evaluation of the safety and tolerability of AL102 in subjects with progressing desmoid tumors as defined by as defined by the frequency and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: Approximately 1.5 years

  2. Part B: Progression free survival (PFS)

    PFS as defined as the time from randomization until the date of assessment of progression as assessed by BICR based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death by any cause

    Time frame: Approximately 2 years

Secondary outcomes

  1. Part A: Change in Tumor Volume

    Change from baseline to Week 16 in tumor volume as measured by centrally read magnetic resonance imaging (MRI) by Blinded Independent Central Review (BICR)

    Time frame: Approximately 16 weeks

  2. Part B: Overall response rate (ORR)

    Defined as the proportion of subjects with confirmed ORR (complete response \[CR\] and partial response \[PR\]) by BICR based on RECIST v1.1.

    Time frame: Approximately 2 years

  3. Part B: Change in Tumor Volume

    Change from baseline at Week 24 in estimated tumor volume measured by T2 weighted (T2W) MRI or CT by BICR

    Time frame: Approximately 24 weeks

  4. Part B: Duration of response (DOR)

    Defined by the time from confirmed CR or PR (by BICR based on RECIST v1.1) until the earlier of the first documentation of disease progression or death from any cause

    Time frame: Approximately 2 years

  5. Part B: PFS with inclusion of Clinical Progression as an event

    Defined as the time from randomization until the date of radiographic progression as assessed by BICR or clinical progression as assessed by the investigator or death by any cause

    Time frame: Approximately 2 years

  6. Part B: Patient Reported Outcome (PRO)

    Change from baseline to Week 12 in the worst pain intensity (WPI) using GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Symptom Scale and Impact Scale (GODDESS) Desmoid Tumor Symptom Scale (DTSS)

    Time frame: Approximately 12 weeks

  7. Part B: Safety and Tolerability - Adverse Events

    Evaluation of the safety and tolerability of AL102 in subjects with progressing desmoid tumors as defined by the frequency and severity of TEAEs and SAEs

    Time frame: Approximately 2 years

  8. Part B: Safety and Tolerability - Time to Treatment Discontinuation

    Evaluation of the safety and tolerability of AL102 in subjects with progressing desmoid tumors as defined by the time to treatment discontinuation due to TEAE

    Time frame: Approximately 2 years

  9. Open Label Extension (OLE): Safety and Tolerability

    Evaluation of the safety and tolerability of AL102 in subjects with progressing desmoid tumors as defined by the frequency and severity of TEAEs and SAEs

    Time frame: Approximately 12 months

  10. OLE: PFS

    PFS as defined as the time to radiographic progression as assessed by BICR based on RECIST v1.1 or death by any cause

    Time frame: Approximately 12 months

  11. OLE: Confirmed ORR

    Proportion of participants with confirmed ORR (CR and PR) by BICR based on RECIST v1.1

    Time frame: Approximately 12 months

  12. OLE: DOR

    DOR as defined by the time from confirmed CR or PR by BICR based on RECIST v1.1 until the earlier of the first documentation of disease progression or death from any cause

    Time frame: Approximately 12 months

  13. OLE: PFS

    PFS as defined as the time to radiographic progression as assessed by BICR based on RECIST v1.1 or clinical progression as assessed by the investigator or death by any cause

    Time frame: Approximately 12 months

  14. OLE: PRO - GODDESS DTSS Total Symptom Score

    Change from baseline in quality of life (QoL) as determined by GODDESS DTSS Total Symptom Score

    Time frame: Approximately 12 months

  15. OLE: PRO - GODDESS DTSS Physical Functioning Domain Score

    Change from baseline in QoL as determined by GODDESS DTSS Physical Functioning Domain Score

    Time frame: Approximately 12 months

  16. OLE: PRO - WPI using GODDESS DTSS Item 1

    Change from baseline in QoL as determined by WPI using GODDESS DTSS Item 1

    Time frame: Approximately 12 months

07

Study locations

53 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Dec 2025, 51 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2021
First posted
May 4, 2021
StartActual
Sep 1, 2021
Primary completionActual
Dec 3, 2025
CompletionEst.
Dec 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04871282
Lead sponsor
Immunome, Inc.
Responsible party
Sponsor
First posted
May 4, 2021
Start date
Sep 1, 2021
Primary completion
Dec 3, 2025
Completion
Dec 2026 (estimated)
Last update
Jun 8, 2026

Study contacts

Mrinal Gounder, MD
principal investigator · MSKCC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BMS-986115

Start the discussion